For US Healthcare Professionals Only

Make DORIBAX® your carbapenem for in vitro* potency against
P aeruginosa

TRUST Study: Consistently low MIC90 against P aeruginosa*1

DORIBAX® in vitro* potency—Consistently low MIC<sub>90</sub> against <em>P aeruginosa</em>

In TRUST 10-13 (2006-2009), surveillance studies supported by Janssen Pharmaceuticals, Inc., P aeruginosa isolates (n=712 for TRUST 10, n=866 for TRUST 11, n=1533 for TRUST 12, n=1215 for TRUST 13) were collected from geographically distributed sites in the US (43 sites for TRUST 10, 45 sites for TRUST 11, 56 sites for TRUST 12, and 65 sites for TRUST 13) and tested against DORIBAX® and several other antibacterials.1

*In vitro activity does not necessarily correlate with clinical results; not intended to convey comparative safety or efficacy.

Explore more about DORIBAX® and low MICs against P aeruginosa isolates of concern.

Please see Select Usage Information below.

Reference



 

Select Usage Information

 

  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy